Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

M.V.I. ADULT Highlights (multi-vitamin infusion - ADULT)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use M.V.I. ADULT™ safely and effectively. See full prescribing information for M.V.I. ADULT.

M.V.I. ADULT (multiple vitamins injection), for intravenous use
Initial U.S. Approval: 2004

INDICATIONS AND USAGE

M.V.I. Adult is a combination of vitamins indicated for prevention of vitamin deficiency in adults and pediatric patients aged 11 years and above receiving parenteral nutrition. (1)

DOSAGE AND ADMINISTRATION

M.V.I. Adult is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K, folic acid, biotin, and vitamin B12. (2.1)
Recommended daily dosage is 10 mL. (2.2)
Administer by intravenous infusion after dilution. (2.1)
Supplied as a single-dose and a pharmacy bulk package:
M.V.I. Adult Single Dose: consists of two vials labeled Vial 1 and Vial 2. Transfer contents of Vial 1 to Vial 2. The mixed solution (10 mL) will provide a single 10 mL dose. Use within 4 hours of puncture. (2.1, 2.3)
M.V.I. Adult Pharmacy Bulk Package: consists of two vials labeled Vial 1 and Vial 2. Transfer the contents of Vial 1 to Vial 2. The mixed solution (100 mL) will provide ten 10 mL single doses to patients in a pharmacy admixture program. Use within 4 hours of puncture. (2.12.3)
Prior to intravenous administration, dilute the once daily dose of 10 mL by adding to at least 500 to 1,000 mL intravenous parenteral nutrition solution containing dextrose or saline. (2.3)
After dilution in an intravenous infusion, refrigerate resulting solution unless used immediately. Use solution within 24 hours after dilution. (2.3)
Monitor blood vitamin concentrations. (2.4)
See Full Prescribing Information for drug incompatibilities. (2.5)

DOSAGE FORMS AND STRENGTHS

Injection (3):
Single dose: consists of two vials labeled Vial 1 (5 mL) and Vial 2 (5 mL).
Pharmacy bulk package: consists of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL).
See Full Prescribing Information for vitamin strengths. (3, 11)

CONTRAINDICATIONS

Hypersensitivity to any of the vitamins or excipients. (4)
Existing hypervitaminosis. (4)

WARNINGS AND PRECAUTIONS

Decreased Anticoagulant Effect of Warfarin: Periodically monitor prothrombin time/INR. (5.1)
Risk of Aluminum Toxicity: For at risk patients (renal failure or those with prolonged therapy), periodically monitor aluminum levels with prolonged administration. (5.2)
Low Vitamin A levels: Monitor vitamin A levels. (5.3)
Allergic Reactions: to thiamine may occur. (5.4)
Hypervitaminosis A: Patients with renal failure or liver disease may be at higher risk. (5.5)
Interferes with Megaloblastic Anemia Diagnosis: Avoid use during testing for this disorder. (5.6)
Risk of Vitamin Deficiencies or Excess: Monitor blood vitamin concentrations. (5.7)
False Negative Urine Glucose Tests: May occur due to vitamin C. (5.8)

ADVERSE REACTIONS

Adverse reactions have included anaphylaxis, rash, erythema, pruritus, headache, dizziness, agitation, anxiety, diplopia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Effect of M.V.I. Adult on other drugs:

Phenytoin: Folic acid may decrease phenytoin blood levels and increase the risk of seizure activity. (7.1)
Methotrexate: Folic acid may decrease response to methotrexate. (7.1)
Levodopa: Pyridoxine may decrease blood levels of levodopa and levodopa efficacy may decrease. (7.1)
Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin. (7.1)
Bleomycin: Ascorbic acid and riboflavin may reduce the activity of bleomycin. (7.1)

Effects of other drugs on M.V.I. Adult:

Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements. (7.2)
Phenytoin: May decrease folic acid concentrations. (7.2)

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation: Pregnant and lactating women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonpregnant and nonlactating women. (8.18.2)
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 11 years have not been established. (8.4)
Renal Impairment: Monitor renal function, calcium, phosphorus and vitamin A levels. (8.6)
Hepatic Impairment: Monitor vitamin A levels. (8.7)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2020

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event